| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/06/2013 | EP2552449A2 Improved methods and compositions for safe and effective treatment of erythema |
| 02/06/2013 | EP2552448A2 Improved methods and compositions for safe and effective treatment of telangiectasia |
| 02/06/2013 | EP2552447A1 Stable pharmaceutical composition of imatinib |
| 02/06/2013 | EP2552446A1 Method for treating schizophrenia and related diseases |
| 02/06/2013 | EP2552445A1 Opioid receptor antagonist (naltrexone) for use in treating herpes zoster disease |
| 02/06/2013 | EP2552444A1 NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NMPRTase) INHIBITOR FOR GLIOMA THERAPY |
| 02/06/2013 | EP2552443A1 Improved treatment of renal cell carcinoma |
| 02/06/2013 | EP2552442A1 Pharmaceutical composition comprising an sglt2 inhibitor and a ppar- gamma agonist and uses thereof |
| 02/06/2013 | EP2552441A1 Uses of dgat1 inhibitors |
| 02/06/2013 | EP2552440A1 Novel combination and use |
| 02/06/2013 | EP2552439A1 Methods of enhancing drug delivery and effectiveness of therapeutic agents |
| 02/06/2013 | EP2552438A1 Methods of treatment of hepatocellular carcinoma |
| 02/06/2013 | EP2552437A2 Microbiologically stable, easily applicable preparations comprising anionic or cationic active substances |
| 02/06/2013 | EP2552436A1 Pharmaceutical composition comprising gemfibrozil and cyp2c8 and/or oatp substrate drug such as repaglinide |
| 02/06/2013 | EP2552435A1 Methods and compositions comprising ampk activator (metformin/troglitazone) for the treatment of myotonic dystrophy type 1 (dm1) |
| 02/06/2013 | EP2552434A2 Peptides and their use |
| 02/06/2013 | EP2552433A2 Compositions and methods for the treatment of somatosensory disorders |
| 02/06/2013 | EP2552432A2 Use of at least one dialkyl thiosulfonate or thiosulfinate for reducing the number of apicomplexa in an animal |
| 02/06/2013 | EP2552431A1 Carvacrol/thymol composition for the treatment of salmonid rickettsial septicemia and infectious salmon anemia |
| 02/06/2013 | EP2552430A1 Use of the phytocannabinoid cannabidivarin (cbdv) in the treatment of epilepsy |
| 02/06/2013 | EP2552429A1 Combination therapy comprising a ccr5 antagonist, a hiv-1 protease inhibitor and a pharmacokinetic enhancer |
| 02/06/2013 | EP2552428A1 Pkc inhibitors for the treatment of b-cell lymphoma having chronic active b-cell-receptor signalling |
| 02/06/2013 | EP2552427A1 Compositions for dental treatment comprising lipoteichoic acids or parts thereof like mono- or polyglycerphosphates |
| 02/06/2013 | EP2552426A2 Intravaginal drug delivery device |
| 02/06/2013 | EP2552419A2 Modified release dosage form comprising desvenlafaxine or salts thereof |
| 02/06/2013 | EP2552418A2 A fast dissolving pharmaceutical composition |
| 02/06/2013 | EP2552415A1 Methods of treating cancer |
| 02/06/2013 | EP2552414A1 Pharmaceutical powder composition for inhalation |
| 02/06/2013 | EP2552410A2 Method for preserving alum adjuvants and alum-adjuvanted vaccines |
| 02/06/2013 | EP2552409A1 Bioadhesive compositions of local anaesthetics |
| 02/06/2013 | EP2552408A2 Water-free pharmaceutical compositions suitable for local anaesthetics |
| 02/06/2013 | EP2552405A2 Method for producing a drug delivery system on the basis of polyelectrolyte complexes |
| 02/06/2013 | EP2552404A1 Parenteral pharmaceutical form which releases aromatse inhibitor and gestagens, for the treatment of endometriosis |
| 02/06/2013 | EP2552403A2 A fast dissolving pharmaceutical composition |
| 02/06/2013 | EP2552402A2 Multilayer melt-extruded film |
| 02/06/2013 | EP2552397A2 Cosmetic and pharmaceutical composition comprising n-acetylglucosamine-6-phosphate |
| 02/06/2013 | EP2552388A2 Microbiologically stable, easily applicable preparations |
| 02/06/2013 | EP2552347A1 Method for stimulating the reproductive capacity in a bull, and composition for stimulating the reproductive capacity in a bull |
| 02/06/2013 | EP2552236A1 Emulsions useful in beverages |
| 02/06/2013 | EP2552216A1 Derivatives of 1-amino-2-cyclopropylethylboronic acid |
| 02/06/2013 | EP2552214A1 Pyrazolyl-pyrimidines as kinase inhibitors |
| 02/06/2013 | EP2552211A1 Indazolyl-pyrimidines as kinase inhibitors |
| 02/06/2013 | EP2552210A1 Formulations of mazindol |
| 02/06/2013 | EP2552209A1 Novel spiro imidazolone derivatives as glucagon receptor antagonists, compositions, and methods for their use |
| 02/06/2013 | EP2552208A1 Imidazolyl-imidazoles as kinase inhibitors |
| 02/06/2013 | EP2552207A1 Sweet flavor modifier |
| 02/06/2013 | EP2552205A1 Methods of improving quality of sleep |
| 02/06/2013 | EP2552204A1 Hypersulfated glucopyranosides |
| 02/06/2013 | EP2552203A1 Compounds and pharmaceutical compositions for the treatment of viral infections |
| 02/06/2013 | EP2552200A1 Dimethyl sulfoxide (dmso) formulations for treating autism |
| 02/06/2013 | EP2552199A1 Improved stable aqueous formulation of (e)-4-carboxystyryl-4-chlorobenzyl sulfone |
| 02/06/2013 | EP2206781A9 Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
| 02/06/2013 | CN202714946U Estrus synchronization vagina embolism for sheep |
| 02/06/2013 | CN1993327B 3-Carbamoyl-2-pyridone derivative |
| 02/06/2013 | CN1950082B Bicyclic and bridged nitrogen heterocycles |
| 02/06/2013 | CN1938298B Methods for minimizing thioamide impurities |
| 02/06/2013 | CN1378445B Drug releasing biodegradable fiber implant |
| 02/06/2013 | CN102918157A SiRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions |
| 02/06/2013 | CN102918118A Fluorescent dye material and use thereof |
| 02/06/2013 | CN102918050A Arylfluorophosphate inhibitors of intestinal apical membrane sodium/phosphate co-transport |
| 02/06/2013 | CN102918049A Fused tricyclic silyl compounds and methods of use thereof for the treatment of viral diseases |
| 02/06/2013 | CN102918048A Cephem compound having catechol group |
| 02/06/2013 | CN102918047A Cephem compound having pseudo-catechol group |
| 02/06/2013 | CN102918046A Inhibitors of jnk |
| 02/06/2013 | CN102918045A Substituted pyrrolotriazines as protein kinase inhibitors |
| 02/06/2013 | CN102918043A Pyrrolopyrimidine compounds as inhibitors of CDK4/6 |
| 02/06/2013 | CN102918042A 8-methyl-1-phenyl-imidazol[1,5-a]pyrazine compounds |
| 02/06/2013 | CN102918040A Purinone derivative |
| 02/06/2013 | CN102918038A 新的多晶型物 The new polymorph of |
| 02/06/2013 | CN102918036A 5-amino-3,6-dihydro-1h-pyrazin-2-one derivatives useful as inhibitors of beta-secretase (bace) |
| 02/06/2013 | CN102918035A 2 -amino- pyrimidine derivatives useful as inhibitors of jnk |
| 02/06/2013 | CN102918034A Multisubstituted aromatic compounds as inhibitors of thrombin |
| 02/06/2013 | CN102918031A Radiolabeled compounds and methods thereof |
| 02/06/2013 | CN102918027A Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| 02/06/2013 | CN102918021A Nicotinic receptor non-competitive antagonists |
| 02/06/2013 | CN102917757A Personal care compositions comprising a methyl naphthalenyl ketone or a derivative thereof |
| 02/06/2013 | CN102917711A Heparan sulfate replacement therapy |
| 02/06/2013 | CN102917710A Esterified Polysaccharide Osmotics |
| 02/06/2013 | CN102917709A Furin-knockdown and GM-CSF-augmented (FANG) cancer vaccine |
| 02/06/2013 | CN102917708A Processes for preparing macrolides and ketolides and intermediates therefor |
| 02/06/2013 | CN102917707A Aza-indole derivatives useful as modulators of FAAH |
| 02/06/2013 | CN102917706A Composition for treating chronic hepatitis B, containing clevudine and adefovir dipivoxil |
| 02/06/2013 | CN102917705A PPAR-sparing thiazolidinediones and combinations for the treatment of neurodegenerative diseases |
| 02/06/2013 | CN102917704A Oxazole derivatives useful as modulators of FAAH |
| 02/06/2013 | CN102917703A Novel EP4 agonist |
| 02/06/2013 | CN102917702A Zinc-containing compositions for the treatment of diseases, illnesses and syndromes associated with exposure to pore forming toxins |
| 02/06/2013 | CN102917701A Use of riluzole to treat or prevent the adverse effects of antineoplastic agents |
| 02/06/2013 | CN102917700A Neurodegenerative disease therapeutic agent |
| 02/06/2013 | CN102917699A Dendrimer compositions and methods of synthesis |
| 02/06/2013 | CN102917698A Dosage regimen of diaryl sulfide derivatives |
| 02/06/2013 | CN102917696A Aceclofenac slow-release preparation providing an optimum pharmacological clinical effect when administered once a day |
| 02/06/2013 | CN102917695A Atazanavir sulfate formulations with improved ph effect |
| 02/06/2013 | CN102917687A Injectable emulsion of sedative hypnotic agent |
| 02/06/2013 | CN102917604A Compositions for masking the flavor of nutrients and methods for making same |
| 02/06/2013 | CN102917592A Risperidone immunoassay |
| 02/06/2013 | CN102917589A Compositions comprising enzyme-cleavable opioid prodrugs and inhibitors thereof |
| 02/06/2013 | CN102917588A Chemical compounds |
| 02/06/2013 | CN102917587A Lenalidomide and thalidomide immunoassays |
| 02/06/2013 | CN102917586A Hypersulfated glucopyranosides |
| 02/06/2013 | CN102917585A Compounds and pharmaceutical compositions for the treatment of viral infections |